Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
Titel:
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
Auteur:
Oliveira, M. Falato, C. Cejalvo, J.M. Vila, M. Margelí Tolosa, P. Salvador-Bofill, F.J. Cruz, J. Arumi, M. Luna, A.M. Guerra, J.A. Vidal, M. Martínez-Sáez, O. Paré, L. González-Farré, B. Sanfeliu, E. Ciruelos, E. Espinosa-Bravo, M. Pernas, S. Izarzugaza, Y. Esker, S. Fan, P.-D. Parul, P. Santhanagopal, A. Sellami, D. Villacampa, G. Ferrero-Cafiero, J.M. Pascual, T. Prat, A.